Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chemotherapy Utility in GenesWell BCT Low-Risk Breast Cancer
NCT04278469Recruiting
- Sponsor
- Gencurix
- Start
- Jan 2019
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
Randomised, open-label trial in Hormone-Receptor-Positive Breast Cancer (2 arms), sponsored by Gencurix. Primary endpoint: Distant Metastasis Free Survival at 10 years. Started Jan 2019; status: recruiting.
02
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT04278469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04278469.